|
1.
|
K Washington7th edition of the AJCC cancer
staging manual: stomachAnn Surg
Oncol1730773079201010.1245/s10434-010-1362-z20882416
|
|
2.
|
S LiangL HeX ZhaoMicroRNA let-7f inhibits
tumor invasion and metastasis by targeting myh9 in human gastric
cancerPloS One6e18409201110.1371/journal.pone.001840921533124
|
|
3.
|
DH RoukosTargeting gastric cancer with
trastuzumab: new clinical practice and innovative developments to
overcome resistanceAnn Surg
Oncol171417201010.1245/s10434-009-0766-019841980
|
|
4.
|
N BalNE KocerME ErtorerET CanpolatF
KayaselcukMaspin, E-selectin, and P-selectin expressions in
papillary thyroid carcinomas and their correlation with prognostic
parametersPathol Res
Pract204743750200810.1016/j.prp.2008.04.01618597952
|
|
5.
|
X ChenJ LiaoY LuX DuanW SunActivation of
the PI3K Akt pathway mediates bone morphogenetic protein 2-induced
invasion of pancreatic cancer cells Panc-1Pathol Oncol
Res17257261201110.1007/s12253-010-9307-120848249
|
|
6.
|
Z XuY ZhangJ JiangEpidermal growth factor
induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1
pancreatic cancer cellsBMC
Cancer10161201010.1186/1471-2407-10-16120423485
|
|
7.
|
AP BhattPM BhendeSH SinD RoyDP DittmerB
DamaniaDual inhibition of PI3K and mTOR inhibits autocrine and
paracrine proliferative loops in PI3K/Akt/mTOR-addicted
lymphomasBlood11544554463201010.1182/blood-2009-10-25108220299510
|
|
8.
|
M SajiMD RingelThe PI3K-Akt-mTOR pathway
in initiation and progression of thyroid tumorsMol Cell
Endocrinol3212028201010.1016/j.mce.2009.10.01619897009
|
|
9.
|
S VignotS FaivreD AguirreE
RaymondmTOR-targeted therapy of cancer with rapamycin
derivativesAnn Oncol16525537200510.1093/annonc/mdi11315728109
|
|
10.
|
D MahalingamK SankhalaA MitaFJ GilesMM
MitaTargeting the mTOR pathway using deforolimus in cancer
therapyFuture Oncol5291303200910.2217/fon.09.919374536
|
|
11.
|
CB ChingDE HanselExpanding therapeutic
targets in bladder cancer: the PI3K/Akt/mTOR pathwayLab
Invest9014061414201010.1038/labinvest.2010.13320661228
|
|
12.
|
JS CarewKR KellyST NawrockiMechanisms of
mTOR inhibitor resistance in cancer therapyTarget
Oncol61727201110.1007/s11523-011-0167-821547705
|
|
13.
|
A YoshimiS GoyamaN Watanabe-OkochiEvi1
represses PTEN expression and activates PI3K/AKT/mTOR via
interactions with polycomb
proteinsBlood11736173628201110.1182/blood-2009-12-26160221289308
|
|
14.
|
M MireutaA DarnelM PollakIGFBP-2
expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway
through Sp1-induced increase in transcriptionGrowth
Factors28243255201010.3109/0897719100374547220370577
|
|
15.
|
C LiuJL WuK XuNeuroprotection by baicalein
in ischemic brain injury involves PTEN/AKT pathwayJ
Neurochem11215001512201010.1111/j.1471-4159.2009.06561.x20050973
|
|
16.
|
SR HamiltonLA AaltonenPathology and
Genetics of Tumors of the Digestive SystemWHO PressGeneva2000
|
|
17.
|
SB EdgeDR ByrdCC ComptonAG FritzF GreeneA
TrottiAJCC cancer staging manual7th editionSpringerNew York2010
|
|
18.
|
X HeQ WeiX ZhangImmunohistochemical
expression of CXCR4 in thyroid carcinomas and thyroid benign
lesionsPathol Res
Pract206712715201010.1016/j.prp.2010.05.00320646838
|
|
19.
|
HY NiuJH WangH LiP HeRapamycin potentiates
cytotoxicity by docetaxel possibly through downregulation of
Survivin in lung cancer cellsJ Exp Clin Canc
Res3028201110.1186/1756-9966-30-2821392382
|
|
20.
|
M ChenJ GuGL DelclosGenetic variations of
the PI3KAKT-mTOR pathway and clinical outcome in muscle invasive
and metastatic bladder cancer
patientsCarcinogenesis3113871391201010.1093/carcin/bgq11020530239
|
|
21.
|
M LiL SongX QinGlycan changes: cancer
metastasis and anti-cancer vaccinesJ
Biosci35665673201010.1007/s12038-010-0073-821289447
|
|
22.
|
F SahinR KannangaiO AdegbolaJZ WangG SuM
TorbensonmTOR and P70 S6 kinase expression in primary liver
neoplasmsClin Cancer
Res1084218425200410.1158/1078-0432.CCR-04-094115623621
|
|
23.
|
K SchmidZ Bago-HorvathW BergerDual
inhibition of EGFR and mTOR pathways in small cell lung cancerBr J
Cancer103622628201010.1038/sj.bjc.660576120683448
|
|
24.
|
K HirashimaY BabaM WatanabePhosphorylated
mTOR expression is associated with poor prognosis for patients with
esophageal squamous cell carcinomaAnn Surg
Oncol1724862493201010.1245/s10434-010-1040-120339946
|
|
25.
|
G YuJ WangY ChenOverexpression of
phosphorylated mammalian target of rapamycin predicts lymph node
metastasis and prognosis of Chinese patients with gastric
cancerClin Cancer
Res1518211829200910.1158/1078-0432.CCR-08-213819223493
|
|
26.
|
J AnH JeongY LeeSU WooJH SeoA
KimPhosphorylated Akt and phosphorylated mTOR expression in breast
invasive carcinomas: analysis of 530 casesJ Breast
Cancer13337348201010.4048/jbc.2010.13.4.337
|
|
27.
|
S BoseS ChandranJM MirochaN BoseThe Akt
pathway in human breast cancer: a tissue-array-based analysisMod
Pathol19238245200610.1038/modpathol.3800525
|
|
28.
|
RJ MotzerB EscudierS OudardEfficacy of
everolimus in advanced renal cell carcinoma: a double-blind,
randomised, placebo-controlled phase III
trialLancet372449456200810.1016/S0140-6736(08)61039-918653228
|
|
29.
|
M MarinovA ZiogasOE PardoAKT/mTOR pathway
activation and BCL-2 family proteins modulate the sensitivity of
human small cell lung cancer cells to RAD001Clin Cancer
Res1512771287200910.1158/1078-0432.CCR-08-216619228731
|
|
30.
|
KH TamZF YangCK LauCT LamRW PangRT
PoonInhibition of mTOR enhances chemosensitivity in hepatocellular
carcinomaCancer
Lett273201209200910.1016/j.canlet.2008.08.01818824293
|
|
31.
|
KS JangYS SongSH JangClinicopathological
significance of nuclear PTEN expression in colorectal
adenocarcinomaHistopathology56229239201010.1111/j.1365-2559.2009.03468.x20102402
|
|
32.
|
T AndjelkovicJ BankovicJ
StojsicCoalterations of p53 and PTEN tumor suppressor genes in
non-small cell lung carcinoma patientsTransl
Res1571928201110.1016/j.trsl.2010.09.00421146147
|
|
33.
|
AM Gonzalez-AnguloJ Ferrer-LozanoK
Stemke-HalePI3K pathway mutations and PTEN levels in primary and
metastatic breast cancerMol Cancer
Ther1010931101201110.1158/1535-7163.MCT-10-108921490305
|
|
34.
|
DJ MulhollandLM TranY LiCell autonomous
role of PTEN in regulating castration-resistant prostate cancer
growthCancer Cell19792804201110.1016/j.ccr.2011.05.00621620777
|
|
35.
|
G HouZ LuM LiuH LiuL XueMutational
analysis of the PTEN gene and its effects in esophageal squamous
cell carcinomaDig Dis
Sci5613151322201110.1007/s10620-010-1474-021116717
|
|
36.
|
MJ LangloisS BergeronG BernatchezThe PTEN
phosphatase controls intestinal epithelial cell polarity and
barrier function: role in colorectal cancer progressionPloS
One5e15742201010.1371/journal.pone.001574221203412
|
|
37.
|
XH LiHC ZhengH TakahashiS MasudaXH YangY
TakanoPTEN expression and mutation in colorectal carcinomasOncol
Rep22757764200919724853
|
|
38.
|
CY GuoXF XuJY WuSF LiuPCR-SSCP-DNA
sequencing method in detecting PTEN gene mutation and its
significance in human gastric cancerWorld J
Gastroenterol1438043811200810.3748/wjg.14.380418609703
|
|
39.
|
M LiL SongX GaoW ChangX QinToll-like
receptor 4 on islet β cells senses expression changes in
high-mobility group box 1 and contributes to the initiation of type
1 diabetesExp Mol Med442602672012
|
|
40.
|
P BakarakosI TheohariA
NomikosImmunohistochemical study of PTEN and phosphorylated mTOR
proteins in familial and sporadic invasive breast
carcinomasHistopathology56876882201010.1111/j.1365-2559.2010.03570.x20636791
|
|
41.
|
ZY ChengXL GuoXY YangPTEN and rapamycin
inhibiting the growth of K562 cells through regulating mTOR
signaling pathwayJ Exp Clin Cancer
Res2787200810.1186/1756-9966-27-8719115995
|
|
42.
|
BY ShorningD GriffithsAR ClarkeLkb1 and
Pten synergise to suppress mTOR-mediated tumorigenesis and
epithelial-mesenchymal transition in the mouse bladderPloS
One6e16209201110.1371/journal.pone.001620921283818
|
